Lexeo Therapeutics (LXEO) to Release Earnings on Monday

Lexeo Therapeutics (NASDAQ:LXEO) is anticipated to release its Q4 2025 results before the market opens on Monday, March 23rd. Analysts expect Lexeo Therapeutics to post earnings of ($0.32) per share for the quarter. Individuals can check the company’s upcoming Q4 2025 earning summary page for the latest details on the call scheduled for Tuesday, March 24, 2026 at 9:30 AM ET.

Lexeo Therapeutics Price Performance

Shares of Lexeo Therapeutics stock opened at $5.65 on Friday. Lexeo Therapeutics has a 52-week low of $1.45 and a 52-week high of $10.99. The company’s fifty day moving average price is $6.97 and its two-hundred day moving average price is $7.92. The firm has a market capitalization of $412.39 million, a PE ratio of -2.09 and a beta of 1.78.

Insider Transactions at Lexeo Therapeutics

In other news, CEO Richard Nolan Townsend sold 10,173 shares of the company’s stock in a transaction dated Wednesday, February 18th. The stock was sold at an average price of $6.38, for a total value of $64,903.74. Following the completion of the transaction, the chief executive officer directly owned 392,483 shares in the company, valued at approximately $2,504,041.54. This represents a 2.53% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 5.30% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in the stock. RA Capital Management L.P. purchased a new position in shares of Lexeo Therapeutics in the fourth quarter worth approximately $49,650,000. Paradigm Biocapital Advisors LP purchased a new stake in Lexeo Therapeutics in the 4th quarter worth $47,299,000. Balyasny Asset Management L.P. bought a new stake in Lexeo Therapeutics during the 2nd quarter valued at approximately $16,117,000. State Street Corp raised its position in shares of Lexeo Therapeutics by 485.1% during the fourth quarter. State Street Corp now owns 3,187,722 shares of the company’s stock valued at $31,654,000 after buying an additional 2,642,877 shares during the last quarter. Finally, Orbimed Advisors LLC purchased a new stake in Lexeo Therapeutics in the 4th quarter worth $21,101,000. 60.67% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of research analysts recently commented on LXEO shares. Raymond James Financial began coverage on shares of Lexeo Therapeutics in a research note on Wednesday, December 17th. They issued a “strong-buy” rating and a $25.00 price target on the stock. Oppenheimer reaffirmed an “outperform” rating and set a $20.00 price objective on shares of Lexeo Therapeutics in a research report on Wednesday, December 10th. Chardan Capital reaffirmed a “buy” rating and issued a $17.00 target price on shares of Lexeo Therapeutics in a report on Tuesday, January 13th. HC Wainwright reduced their price target on shares of Lexeo Therapeutics from $13.00 to $10.00 and set a “buy” rating on the stock in a research note on Tuesday, January 13th. Finally, Cantor Fitzgerald started coverage on Lexeo Therapeutics in a research report on Monday, December 1st. They set an “overweight” rating and a $19.00 price objective on the stock. One analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $19.00.

About Lexeo Therapeutics

Lexeo Therapeutics, Inc is a clinical‐stage biotechnology company dedicated to developing novel, precision‐designed therapies for central nervous system disorders. The company’s research platform leverages advanced medicinal chemistry to create next‐generation psychedelic-inspired compounds aimed at treating a range of mental health conditions, including anxiety, depression and substance use disorders.

The company’s pipeline features proprietary synthetic molecules engineered to target specific neural pathways while improving safety and tolerability profiles over traditional treatments.